IRIS
Armuzzi, Alessandro
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 17.225
AS - Asia 9.254
EU - Europa 3.294
SA - Sud America 1.782
AF - Africa 253
Continente sconosciuto - Info sul continente non disponibili 175
OC - Oceania 7
Totale 31.990
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 16.858
SG - Singapore 6.027
BR - Brasile 1.486
CN - Cina 1.335
VN - Vietnam 826
IT - Italia 568
FI - Finlandia 567
DE - Germania 469
IE - Irlanda 440
FR - Francia 300
GB - Regno Unito 257
IN - India 257
HK - Hong Kong 224
NL - Olanda 161
CA - Canada 160
RU - Federazione Russa 132
AR - Argentina 110
BD - Bangladesh 92
NG - Nigeria 88
MX - Messico 87
IQ - Iraq 65
SE - Svezia 62
PL - Polonia 60
ZA - Sudafrica 53
TR - Turchia 52
BE - Belgio 51
EC - Ecuador 50
ID - Indonesia 40
JP - Giappone 40
CO - Colombia 38
PK - Pakistan 38
ES - Italia 35
UA - Ucraina 33
VE - Venezuela 33
SA - Arabia Saudita 31
CZ - Repubblica Ceca 28
IL - Israele 25
IR - Iran 24
CR - Costa Rica 23
UZ - Uzbekistan 23
CL - Cile 22
MA - Marocco 22
TN - Tunisia 20
EG - Egitto 18
PY - Paraguay 18
JM - Giamaica 17
JO - Giordania 17
KE - Kenya 16
LT - Lituania 16
MY - Malesia 16
TT - Trinidad e Tobago 15
AE - Emirati Arabi Uniti 14
AT - Austria 14
HN - Honduras 14
NP - Nepal 14
GT - Guatemala 13
PE - Perù 12
PH - Filippine 12
PT - Portogallo 12
DO - Repubblica Dominicana 10
RO - Romania 10
CH - Svizzera 9
DZ - Algeria 8
EE - Estonia 8
KZ - Kazakistan 8
OM - Oman 8
UY - Uruguay 8
AZ - Azerbaigian 7
LV - Lettonia 7
PR - Porto Rico 7
PS - Palestinian Territory 7
AL - Albania 6
AU - Australia 6
BG - Bulgaria 6
BY - Bielorussia 6
ET - Etiopia 6
GR - Grecia 6
KG - Kirghizistan 6
NI - Nicaragua 6
SV - El Salvador 6
BO - Bolivia 5
LB - Libano 5
MN - Mongolia 5
RS - Serbia 5
BA - Bosnia-Erzegovina 4
CI - Costa d'Avorio 4
KR - Corea 4
KW - Kuwait 4
SC - Seychelles 4
SY - Repubblica araba siriana 4
TH - Thailandia 4
TW - Taiwan 4
DK - Danimarca 3
HR - Croazia 3
KH - Cambogia 3
MK - Macedonia 3
SI - Slovenia 3
SN - Senegal 3
XK - ???statistics.table.value.countryCode.XK??? 3
AM - Armenia 2
Totale 31.776
Salva come PNG Salva come JPEG
Città #
Singapore 2.471
Chandler 1.937
San Jose 1.729
Ashburn 1.677
The Dalles 1.026
Dallas 940
Shanghai 656
Council Bluffs 611
Helsinki 564
Dublin 439
Princeton 433
Boardman 420
Lawrence 408
New York 361
Wilmington 297
Ho Chi Minh City 281
Los Angeles 274
Santa Clara 262
Beijing 244
Paris 227
Hanoi 205
Hong Kong 204
Milan 190
Falkenstein 187
Phoenix 171
Amsterdam 146
São Paulo 135
Pune 115
London 105
San Mateo 101
Rome 89
Ann Arbor 88
Benin City 84
Seattle 69
Buffalo 68
Brooklyn 59
Chicago 59
Rio de Janeiro 58
North Bergen 53
Warsaw 53
Leawood 50
Atlanta 49
Orem 48
Moscow 44
Frankfurt am Main 41
Munich 41
Montreal 40
Belo Horizonte 39
Brussels 39
Chennai 39
Toronto 37
San Francisco 36
Da Nang 35
Houston 34
Fairfield 33
Mexico City 32
Porto Alegre 32
Assago 30
Curitiba 30
Haiphong 30
Philadelphia 30
Brasília 29
Charlotte 29
Woodbridge 29
Tokyo 27
Columbus 25
Johannesburg 25
Boston 24
Denver 24
Brno 22
Tashkent 22
Figino 21
Miami 21
The Bronx 21
Guayaquil 20
Queens 20
Baghdad 19
Goiânia 19
Milwaukee 19
Dhaka 18
Las Vegas 17
Manchester 17
Mumbai 17
Naples 17
San Diego 17
Stockholm 17
Washington 17
Amman 16
Campinas 16
Guarulhos 16
Nairobi 16
Ankara 15
Cleveland 15
Hillsboro 15
Poplar 15
Riyadh 15
San José 15
Turin 15
Biên Hòa 14
Detroit 14
Totale 19.035
Salva come PNG Salva come JPEG
Nome #
A 1-year follow-up study on checkpoint inhibitor-induced colitis: results from a European consortium 638
Gemelli decision tree Algorithm to Predict the need for home monitoring or hospitalization of confirmed and unconfirmed COVID-19 patients (GAP-Covid19): preliminary results from a retrospective cohort study 198
A liophylized and inactivated colture of Lactobacillus acidophilus increases Helicobacter pylori eradication rate 134
Water supplementation enhances the effect of high-fiber diet on stool frequency and laxative consumption in adult patients with functional constipation 129
Biological therapies for inflammatory bowel disease: Research drives clinics 119
Adalimumab in active ulcerative colitis: A "real-life" observational study 119
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 116
Helicobacter pylori CagA-positive strains affect oxygen free radicals generation by gastric mucosa 116
Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign 111
Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease 109
13C-Breath Tests in the study of microsomal liver function 107
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 106
Adalimumab in the treatment of immune-mediated diseases 105
Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study 105
13C-breath tests in the study of mitochondrial liver function 104
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 104
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 103
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease 102
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates 98
Efficacy and tolerability of antibiotics in patients undergoing H-pylori eradication 98
DNA mismatch repair gene mutations in hereditary non polyposis colorectal cancer (HNPCC) and putative HNPCC (P-HNPCC) Italian families 98
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 97
The PROSIT Cohort of Infliximab Biosimilar in IBD: A Prolonged Follow-up on the Effectiveness and Safety Across Italy 96
3-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure H-pylori infection 95
An Objective Comparison of Vedolizumab and Ustekinumab Effectiveness in Crohn's Disease Patients' Failure to TNF-Alpha Inhibitors 94
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 94
Prevalence of the K469E polymorphism of intercellular adhesion molecule 1 gene in Italian patients with inflammatory bowel disease 94
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management 93
Pomegranate Extract Affects Gut Biofilm Forming Bacteria and Promotes Intestinal Mucosal Healing Regulating the Crosstalk between Epithelial Cells and Intestinal Fibroblasts 93
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases 92
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naive Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European Study 92
A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors 91
Prevalence of and risk factors for Helicobacter pylori infection among healthcare workers at a teaching hospital in Rome: the Catholic University Epidemiological Study 91
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 91
Association of Depression With Incident Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis 91
Safety and efficacy of combining biologics or small molecules for inflammatory bowel disease or immune-mediated inflammatory diseases: A European retrospective observational study 90
Acute pancreatitis and parathyroid carcinoma: a case report and literature review 89
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 88
Dysfunctional Extracellular Matrix Remodeling Supports Perianal Fistulizing Crohn's Disease by a Mechanoregulated Activation of the Epithelial-to-Mesenchymal Transition 88
Ustekinumab in the management of Crohn's disease: Expert opinion 87
Activity of Crohn's disease and small bowel contract-enhanced ultrasound findings 86
H-pylori poliantibiotic resistant strains in dyspeptic patients not eradicated by two consecutive triple eradication regimens 86
Adhesion molecules in inflammatory bowel disease: Therapeutic implications for gut inflammation 85
Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease 85
Antibodies to Saccharomyces cerevisiae: Are they useful in clinical practice? 84
ECCO Guidelines on Therapeutics in Crohn's Disease: medical treatment 84
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission 83
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study 82
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial 82
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 82
Quality of Care in Ulcerative Colitis: A Modified Delphi Panel Approach 81
H-pylori gastric infection and rheumatic diseases 80
Usefulness of C-13-methionine breath test as a non-invasive and dynamic tool to evaluate residual hepatic mitochondrial function 80
Antibiotic resistance of H-pylori strains obtained by dyspeptic patients not eradicated by two consecutive eradication regimens 80
Helicobacter pylori infection affects eosinophilic cationic protein in the gastric juice of patients with idiopathic chronic urticaria 80
FOXP3(+) T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF alpha Agents 80
Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study 80
Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study 79
Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study 79
Ustekinumab versus adalimumab for induction and maintenance therapy in biologic-naive patients with moderately to severely active Crohn's disease: a multicentre, randomised, double-blind, parallel-group, phase 3b trial 79
Burden of disease and patient-reported outcomes in patients with moderate to severe ulcerative colitis in the last 12 months - Multicenter European cohort study 79
A novel pathogenic role for microvasculature in inflammatory bowel disease 79
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment 79
The learning curve for using intestinal ultrasonography 78
Haplotypic analysis of heat shock protein 70 (HSP70) single nucleotide polymorphisms (SNPs) in susceptibility and phenotype of inflammatory bowel disease (IBD) 77
Dietary Fiber in Inflammatory Bowel Disease: Are We Ready to Change the Paradigm? 77
HELICOBACTER-PYLORI GASTRITIS WITH CYTOTOXIN ASSOCIATED PROTEIN ANTIBODIES (CAGA) - A COMPUTER-AIDED EVALUATION OF INFLAMMATORY CELL INFILTRATION IN THE LAMINA PROPRIA, ATROPHIC GASTRITIS AND ACQUIRED MALT 77
Family history of peptic ulcer and a positive C-13 urea breath test are predictive of gastroduodenal ulcer disease in uninvestigated dyspeptic patients 77
Advancements in Endoscopic Resection for Colitis-Associated Colorectal Neoplasia in Inflammatory Bowel Disease: Turning Visible into Resectable 77
Unmet Medical Needs in the Management of Ulcerative Colitis: Results of an Italian Delphi Consensus 77
Artificial intelligence and inflammatory bowel disease: Where are we going? 77
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease 76
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? 76
Long-term scheduled therapy with infliximab in inflammatory bowel disease 76
Role of sucralfate in gastrointestinal diseases 76
Difference in treatment outcomes between clinical trials and "real-life" clinical practice: ustekinumab in ulcerative colitis 76
Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study 75
Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease 75
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study 74
Helicobacter pylori eradication ameliorates migraine: An extended follow up study 74
IBD: Infliximab dose optimization in IBD-proactive or reactive? 74
C-13 urea breath test for predicting resistance to therapy in Helicobacter pylori infection 74
Biosimilars: The viewpoint of Italian patients with inflammatory bowel disease 73
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders 73
Haplotype-specific linkage disequilibrium patterns define the genetic topography of the human MHC 73
Aminopyrine and methacetin 13C-breath tests to assess hepatic function in HCV-related chronic liver disease 73
Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by C-13-octanoate breath test 73
Management of patients with complex perianal fistulas in Crohn's disease: Optimal patient flow in the Italian clinical reality 73
The PROSIT-BIO Cohort of the IG-IBD: A Prospective Observational Study of Patients With Inflammatory Bowel Disease Treated With Infliximab BioSimilars 73
Editorial: effectiveness and safety of vedolizumab in a matched cohort of elderly and non‐elderly patients with inflammatory bowel disease—the IG‐IBD LIVE study. Authors' reply 73
Incidence and symptoms related to Helicobacter pylori infection in dyspeptic patients 72
Inflammatory Bowel Disease Phenotype as Risk Factor for Cancer in a Prospective Multicentre Nested Case-Control IG-IBD Study 72
Role of helicobacter pylori in gastroesophageal reflux disease 72
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results 72
Comparison of two strategies for the management of postoperative recurrence in Crohn’s disease patients with one clinical risk factor: A multicentre IG‐IBD study 72
Non-invasive assessment of human hepatic mitochondrial function through the C-13-methionine breath test 72
Disease patterns in late-onset ulcerative colitis: Results from the " IG-IBD ""AGED study""" 72
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment 72
Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use 72
Deep Remission at 1 Year Prevents Progression of Early Crohn's Disease 72
Totale 9.286
Salva come PNG Salva come JPEG
Categoria #
all - tutte 206.921
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 206.921
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022297 0 0 0 68 5 3 9 37 27 33 67 48
2022/20235.528 881 67 455 612 462 568 7 567 1.025 476 349 59
2023/20243.458 228 332 814 263 115 396 188 115 29 219 345 414
2024/20254.764 100 30 50 64 60 469 230 321 931 1.287 619 603
2025/202613.039 1.878 845 907 1.095 470 710 3.883 649 691 815 409 687
2026/20274.346 515 884 2.282 665 0 0 0 0 0 0 0 0
Totale 31.990